Reporting on cannabis policy, science, business, and culture from The Alkaloid.
newsletter
What if the trip was never the point? A new class of compounds promises the brain-rewiring of psychedelics without the hallucination, and the first non-tripping antidepressant is heading for trials you can run from your own couch.
newsletter
Scientists finally caught the munchies in the act. A new study shows cannabis turns up the brain's reward for food, spikes the hunger hormone, and sharpens taste. The same circuit could feed people who can't eat.
newsletter
Psychedelic science spent sixty years studying the young. A new UC Berkeley study finally hands the eye mask to people between 60 and 85 — and asks whether an old brain can still change its mind.
newsletter
A lab in Israel engineered one tobacco plant to make psilocybin, DMT, bufotenin, 5-MeO-DMT, and psilocin at once. The molecules just left the mushroom and the toad behind. What that means for cost, supply, and a drug law written when the drug and its source were the same thing.
newsletter
Last fall Congress redefined hemp and capped legal products at 0.4 milligrams of THC. The rule erases an estimated 95 percent of the market by November. Now the same White House that signed it is asking Congress to carve out an exception before the deadline it created.
newsletter
The FDA lost its commissioner in May. Four weeks from now, the agency is supposed to help decide whether all marijuana moves to Schedule III. The most powerful job in American drug policy is being done by a caretaker, and almost nobody is talking about it.
newsletter
In April, the DOJ rescheduled medical cannabis to Schedule III — handing operators billions in tax relief. It opened zero prison cells. Now 29 members of Congress want Trump to commute the sentences of roughly 3,000 people still serving federal time for a drug the government just reclassified.
Field Notes
Virginia just vetoed the bill that would have launched legal cannabis sales. The political story is small. The larger one — five years of legal possession without legal sales has produced the country's most documented case of what gray markets actually cost.
newsletter
The DOJ just rescheduled medical cannabis to Schedule III after fifty-six years. Billions in tax relief, new research access, and zero relief for the people prohibition harmed most. What the April 22 order changed, and what it deliberately left untouched.
newsletter
For as long as cannabis has been cultivated, the leaves have been an afterthought — biomass, waste, compost. A team of analytical chemists at Stellenbosch University just identified 79 phenolic compounds in those leaves, 25 never reported before, including 16 rare flavoalkaloids.
newsletter
Walk into a high-end dispensary in Brooklyn, Toronto, or West Hollywood and try to find a marijuana leaf on the wall. You probably won't. Cannabis legalization has produced something almost no one predicted — a design renaissance. What gets left out is its own kind of statement.
newsletter
On November 12, 2026, the federal government will effectively ban most hemp-derived THC products — delta-8 gummies, THCA flower, HHC vapes. Buried in the shutdown spending bill, the provision affects 95% of products on the market. Seven months to adapt.